Merck 3Q Revenues: $5.9 billion (-2%) 3Q Earnings: $1.1 billion (-28%) YTD Revenues: $17.8 billion (-1%) YTD Earnings: $6.2 billion (+26%) Comments: Januvia sales were $379 million in the quarter (+105%). Sales of Isentress were $107 million. Worldwide sales of Singulair were $1.0 billion (+1%). Cozaar and Hyzaar sales were $888 million (+9%). Combined worldwide sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough joint venture, were $1.1 billion in the quarter (-1...